Search
Ibandronate
go.drugbank.com/drugs/DB00710ApprovedInvestigationalIbandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid]. … [L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.[A203138] Ibandronate was granted FDA approval on 16 May 2003.[L13805]
Mixtures: IBONE D®, IBONE D 30000Products: BONVIVA® 3 MG/3 ML., BONDRONAT 2 MG/2 ML AMPUL, 5 ADETOxacillin
go.drugbank.com/drugs/DB00713ApprovedInvestigationalAn antibiotic similar to flucloxacillin used in resistant staphylococci infections.
Categories: Heterocyclic Compounds, 2-RingSynonyms: (2S,5R,6R)-3,3-dimethyl-6-{[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, (5-methyl-3-phenyl-4-isoxazolyl)penicillinParoxetine
go.drugbank.com/drugs/DB00715ApprovedInvestigationalParoxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. … Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine, (−)-(3S,4R)-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidineMethoxamine
go.drugbank.com/drugs/DB00723ApprovedInvestigationalWithdrawnAn alpha-adrenergic agonist that causes prolonged peripheral vasoconstriction. It has little if any direct effect on the central nervous system.
Categories: Adrenergic alpha-1 Receptor AgonistsHomatropine methylbromide
go.drugbank.com/drugs/DB00725ApprovedHomatropine methylbromide is a quaternary ammonium muscarinic acetylcholine receptor antagonist belonging to the group of medicines called anti-muscarinics.
Mixtures: Debiline H, BONESPAS® TABLETASSynonyms: 3-alpha-Hydroxy-8-methyl-1-alpha-H,5-alpha-H-tropanium bromide mandelate, 8-Methylhomatropinium bromideNateglinide
go.drugbank.com/drugs/DB00731ApprovedApproximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. … It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesOlive oil
go.drugbank.com/drugs/DB09567ApprovedInvestigationalUsed as a source of fatty acids in total parenteral nutrition and as an additive in some cosmetic products [FDA Label].
Mixtures: aspen nutrition Omega 3-6-9, Numeta G 13 % E Emulsion zur InfusionProducts: MediORO WInclisiran
go.drugbank.com/drugs/DB14901ApprovedInvestigationalInclisiran is a long-acting, synthetic small interfering RNA (siRNA) directed against proprotein convertase subtilisin-kexin type 9 (PCSK9), which is a serine protease that regulates plasma low-density … lipoprotein cholesterol (LDL-C) levels.
Categories: Compounds used in a research, industrial, or household setting, Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) InhibitorsProducts: LYPTİMZİA 284 MG/1,5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETApitegromab
go.drugbank.com/drugs/DB16096InvestigationalApitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).
Synonyms: Immunoglobulin g4 (234-proline), anti-(human progrowth differentiation factor 8) (human monoclonal srk-015 .gamma.4-chain), disulfide with human monoclonal srk-015 .lambda.-chain, dimerUstekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigationalUstekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. … [A187349] It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling
Products: STELARA® 90 MG/ML, STELARA® 45 MG/0.5 ML